论文部分内容阅读
本研究探讨多发性骨髓瘤(MM)患者的循环骨髓瘤细胞(circulating myeloma cells,CMC)和骨髓骨髓瘤细胞(marrow myeloma cells,MMC)的相关性及其临床意义。采用四色流式细胞术对55例MM患者同时检测CMC和MMC的百分率,并结合患者的β2微球蛋白(β2-MG)、血浆白蛋白(Alb)水平、染色体核型、肾功能等预后相关指标进行系统分析。将患者分成4组:A组为同时检测到CMC和MMC患者;B组为仅检测到MMC患者;C组为仅检测到CMC患者;D组为未检测到瘤细胞患者。结果发现:与其他各组相比,A组的β2-MG和肌酐浓度显著增高,白蛋白水平明显低下。就上述预后因素而言,在检测到与未检测到骨髓瘤细胞患者之间,差异有统计学意义。初发、复发/难治患者的CMC和MMC百分率明显高于部分缓解和完全缓解的患者。骨髓瘤患者CMC与MMC显著相关。结论:骨髓瘤患者CMC和MMC百分率不仅反映肿瘤负荷,而且预示病情进展,特别是同时检测到CMC和MMC的多发性骨髓瘤患者。
This study was aimed to investigate the relationship between circulating myeloma cells (CMC) and myeloma cells (MMC) in patients with multiple myeloma (MM) and its clinical significance. The percentage of CMC and MMC in 55 cases of MM patients was detected by four-color flow cytometry. Combined with the prognosis of patients with β2 microglobulin (β2-MG), plasma albumin (Alb), chromosome karyotype and renal function Related indicators for systematic analysis. The patients were divided into 4 groups: group A were patients with both CMC and MMC; group B with MMC only; group C with CMC only; group D with undetected tumor cells. The results showed that: Compared with other groups, A group of β2-MG and creatinine concentrations were significantly increased, albumin levels were significantly lower. In terms of the above prognostic factors, there was a statistically significant difference between patients with and without detection of myeloma cells. The percentage of CMC and MMC in patients with newly diagnosed, relapsed / refractory patients was significantly higher than that in patients with partially relieved and complete remission. CMC and MMC were significantly associated with myeloma patients. CONCLUSION: The percentage of CMC and MMC in myeloma patients not only reflects tumor burden but also predicts progression, particularly in patients with multiple myeloma who have both CMC and MMC.